Divalproex Sodium Tablet, Film Coated, Extended Release
Product Images NDC 68084-310

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 68084-310). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

250 mg Blister

250 mg Blister
FDA Label Image

250 mg Carton

250 mg Carton
This is a pharmaceutical package of Divalproex Sodium Extended-release Tablets with NDC 68084-310-01. This medication has the usual dosage mentioned in the package insert or prescribing information. Each tablet contains Divalproex sodium, USP equivalent to valproic acid 250 mg. It is advised to keep the drug out of reach of children and not use if the blister is open or broken. This product is manufactured by BluePont Laboratories and is distributed by American Health Packaging. Pharmacists are advised to dispense this medication with the accompanying medication guide to each patient. Storage between 20°C to 30°C is advised.*
FDA Label Image

500 mg Blister

500 mg Blister
FDA Label Image

500 mg Carton

500 mg Carton
This is a medication package containing 100 extended-release tablets of Divalproex Sodium, a medication used for treating seizure disorders, bipolar disorder, and prevention of migraines. It is for prescription use only and each tablet contains 500 mg of Divalproex sodium. The package includes a medication guide to be given to each patient. The tablets should be stored at a temperature between 20°C to 25°C. It is manufactured and distributed by American Health Packaging in Columbus, Ohio.*
FDA Label Image

Ahp041501

Ahp041501
FDA Label Image

Ahp31001

Ahp31001
FDA Label Image

Figure 1

Figure 1
FDA Label Image

Figure 2

Figure 2
This document appears to show a chart comparing two different dosages of delayed-release divalproex sodium tablets and their effects on the rate of CPS (Central Pain Syndrome) in patients. Unfortunately, there is not enough context to provide a more detailed description.*
FDA Label Image

Figure 3

Figure 3
FDA Label Image

Structure

Structure

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.